Toggle light / dark theme

Researchers have developed a robot capable of performing surgical procedures with the same skill as human doctors by training it using videos of surgeries.

The team from Johns Hopkins and Stanford Universities harnessed imitation learning, a technique that allowed the robot to learn from a vast archive of surgical videos, eliminating the need for programming each move. This approach marks a significant step towards autonomous robotic surgeries, potentially reducing medical errors and increasing precision in operations.

Revolutionary Robot Training

Researchers from Baylor College of Medicine, Stanford University School of Medicine, and their collaborators have identified a novel compound called BHB-Phe, which is naturally produced by the body. Published in the journal Cell, their findings reveal that BHB-Phe regulates appetite and body weight by interacting with neurons in the brain.

Until now, BHB has been known as a compound produced by the liver to be used as fuel. However, in recent years, scientists have found that BHB increases in the body after fasting or exercise, prompting interest in investigating potential beneficial applications in obesity and diabetes.

The rod-shaped tuberculosis (TB) bacterium, which the World Health Organization has once again ranked as the top infectious disease killer globally, is the first single-celled organism ever observed to maintain a consistent growth rate throughout its life cycle. These findings, reported by Tufts University School of Medicine researchers on November 15 in the journal Nature Microbiology, overturn core beliefs of bacterial cell biology and hint at why the deadly pathogen so readily outmaneuvers our immune system and antibiotics.

“The most basic thing you can study in bacteria is how they grow and divide, yet our study reveals that the TB pathogen is playing by a completely different set of rules compared to easier-to-study model organisms,” said Bree Aldridge, a professor of molecular biology and microbiology at the School of Medicine and a professor of biomedical engineering at the School of Engineering, as well as one of the paper’s co-senior authors along with Ariel Amir of the Weizmann Institute of Science.

TB bacteria are successful at surviving in humans because some parts of the infection can quickly evolve within their host, allowing these outliers to avoid detection or resist treatment. If someone has TB, it takes months of various antibiotics to be cured, and even then, this approach is only successful in 85% of patients. Aldridge and her colleagues hypothesize that gaps in our understanding of the basic biology behind this phenomenon have been holding back the development of more effective treatments.

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center and Oregon Health & Science University.

The immune microenvironment around a pancreatic tumor has suppressed immune activity, allowing the tumor to evade attacks by the immune system. The cancer evades the immune system by attracting suppressive cells into the tumor, which limits access of tumor-killing T cells. Because of that so-called immune desert environment, pancreatic ductal adenocarcinoma (PDA), the most common type of pancreatic cancer, has been resistant to immune-based therapies that have successfully treated a variety of other cancers, including melanoma and lung cancer.

In a phase 2 clinical trial, a research team led by Nilofer Azad, M.D., professor of oncology and co-leader of the Kimmel Cancer Center’s Cancer Genetics and Epigenetics Program, and Marina Baretti, M.D., the Jiasheng Chair in Hepato-Biliary Cancer at the Kimmel Cancer Center, tested the safety and efficacy of the combination of two drugs: an immunotherapy, nivolumab, and an epigenetic drug, entinostat — a histone deacetylase inhibitor (HDACi). The combination was studied in a group of 27 patients with advanced PDA who had previously been treated with chemotherapy.

A research team led by Lund University in Sweden has developed an AI tool that traces back the most recent places you have been to.


Microorganisms are organisms, such as bacteria, that are invisible to the naked eye. The word microbiome is used to describe all the microorganisms in a particular environment. Establishing the geographical source of a microbiome sample has been a considerable challenge up to now.

However, in a new study, published in the research journal Genome Biology and Evolution, a research team presents the tool Microbiome Geographic Population Structure (mGPS). It is a unique instrument that uses ground-breaking AI technology to localise samples to specific bodies or water, countries and cities. The researchers discovered that many places have unique bacteria populations, so when you touch a handrail at a train station or bus stop, you pick up bacteria that can then be used to link you back to the exact place.

“In contrast to human DNA, the human microbiome changes constantly when we come into contact with different environments. By tracing where your microorganisms have been recently, we can understand the spread of disease, identify potential sources of infection and localise the emergence of microbial resistance. This tracing also provides forensic keys that can be used in criminal investigations,” says Eran Elhaik, biology researcher at Lund University, who led the new study.

Summary: Researchers have discovered that the NMDA receptor (NMDAR), known for its role in learning and memory, also stabilizes brain activity by setting baseline neural network activity. This stabilization supports the brain’s adaptability amid constant environmental and physiological changes.

The study revealed that blocking NMDARs disrupted this baseline, highlighting their critical role in maintaining neural homeostasis. Findings may revolutionize treatments for conditions like depression, Alzheimer’s, and epilepsy by leveraging NMDAR’s role in brain stability.

Summary: A deep learning AI model developed by researchers significantly accelerates the detection of pathology in animal and human tissue images, surpassing human accuracy in some cases. This AI, trained on high-resolution images from past studies, quickly identifies signs of diseases like cancer that typically take hours for pathologists to detect.

By analyzing gigapixel images with advanced neural networks, the model achieves results in weeks instead of months, revolutionizing research and diagnostic processes. The tool is already aiding disease research in animals and holds transformative potential for human medical diagnostics, particularly for cancer and gene-related illnesses.